Drug intelligence / Profile preview

TRK-130

Development stage: Unknown
Lead developer: Toray Industries
Modality: Small Molecules
Administration: Oral

Overview

TRK-130 is an orally administered small molecule antagonist of the Transient Receptor Potential Melastatin 8 (TRPM8) channel, currently under development by Toray Industries for the treatment of overactive bladder (OAB). TRPM8 is a cold-sensing cation channel found on afferent nerve fibers in the bladder wall; its activation is thought to contribute to the sensory urgency and detrusor overactivity characteristic of OAB. By blocking these channels, TRK-130 aims to reduce the hypersensitivity of the bladder and improve symptoms such as urinary frequency and urgency. The drug is currently being evaluated in Phase 2 clinical trials in Japan.

Targets

KOR (Kappa opioid receptor)DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on TRK-130.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRK-130.

Explore the full profile